Quarter Business Highlights

Principal Financial Data

Fiscal year
(millions of yen)
ending March 2025/Q1 (IFRS) ending March 2025/Q1~2 (IFRS) ending March 2025/Q1~3 (IFRS) ending March 2025/Q1~4 (IFRS) ending March 2026/Q1 (IFRS) ending March 2026/Year Ended (forecast) (IFRS)
Sales revenue 39,131 79,332 121,320 160,232 39,546 166,000
 Pharmaceuticals 33,738 68,496 104,560 138,654 34,163 143,000
 Functional food 5,393 10,836 16,759 21,577 5,382 23,000
Operating income 11,078 17,867 32,752 35,450 10,081 30,000
Profit attributable to owners of the parent 10,264 16,373 28,552 32,558 8,255 24,000
Depreciation and amortization - 2,980 - 6,015 - 7,950
Capital investment - 2,189 - 5,055 - 5,750
R&D expenses 7,497 16,732 23,547 34,341 6,189 39,500
Total assets 265,828 268,542 284,459 283,637 289,625
Total equity 227,462 235,252 247,782 247,340 251,834

Sales revenue

Operating income
 

Net income attributable to owners of the parent

R&D expenses

Cash Flows

Fiscal year
(millions of yen)
ending March 2025/Q1 (IFRS) ending March 2025/Q1~2 (IFRS) ending March 2025/Q1~3 (IFRS) ending March 2025/Q1~4 (IFRS) ending March 2026/Q1 (IFRS)
Cash flow from operating activities 7,004 17,732 17,125 36,126 6,798
Cash flow from investing activities △6,788 △13,340 △11,413 △28,877 908
Cash flow from financing activities △4,328 △4,996 △9,248 △9,902 △4,286

Business Forecast and Outlook

Consolidated business forecast for the fiscal year ending March 2026 (April 1, 2025–March 31, 2026)

Sales revenue Operating income Profit before tax Profit attributable to owners of the parent Basic earnings per share
Consolidated business forecast (millions of yen) 166,000 30,000 30,600 24,000 356.20
Year on year rate 3.6 △15.4 △15.3 △26.3

(Percentage figures represent year-on-year rate of changes.)